niceritrol has been researched along with Uremia in 1 studies
Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.
Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishizawa, Y | 1 |
| Shoji, T | 1 |
| Tabata, T | 1 |
| Inoue, T | 1 |
| Morii, H | 1 |
1 other study available for niceritrol and Uremia
| Article | Year |
|---|---|
Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients.
Topics: Cholesterol, LDL; Cholesterol, VLDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolip | 1999 |